Pharming Group (PHGUF) Rating Reiterated by HC Wainwright

Pharming Group (OTC:PHGUF)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Thursday.

Shares of Pharming Group (PHGUF) traded up 1.08% during mid-day trading on Thursday, reaching $0.94. The company had a trading volume of 65,000 shares. The company’s market capitalization is $475.28 million. Pharming Group has a 1-year low of $0.17 and a 1-year high of $0.98.

TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/10/28/pharming-group-phguf-rating-reiterated-by-hc-wainwright.html.

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply